Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of high pressure-based instruments, consumables, and
related services for the global life sciences industry, this morning announced
its collaboration with NutraFuels, Inc. (OTCQB: NTFU) to advance the
development of a new generation of health and wellness nutraceutical products
based on processing by PBIO’s proprietary Ultra Shear Technology (“UST”)
platform. The companies intend development of a new generation of improved
nutraceutical and other emulsion-based products, such as cosmetics, believing
that nanoemulsions prepared by the UST Platform will have improved quality and
effectiveness compared to current emulsions. “We are pleased to have the
opportunity to work with NTFU’s scientists and manufacturing personnel in the
development of new and improved nutraceutical products utilizing our UST
platform,” PBIO Chief Commercial Officer Dr. Bradford A. Young stated in the
news release. “This proprietary technology employs ultra-high pressure and
extreme shearing forces to create nano-scale emulsions of oil and water with
long-term stability. For many oil-based products, the ability to create very
small, nanometer-sized oil droplets that can effectively dissolve in water
(nanoemulsions) can improve a product’s appearance, sensory and medicinal
benefits. There is a large and growing market opportunity for nutraceutical
products with proven health and wellness benefits. We believe PBI’s UST
platform can help manufacturers accelerate growth and success in this market
with higher quality, water-soluble, oil-based products with superior dietary
absorption and shelf-life.”
To view the full press release, visit http://ibn.fm/q0s6r
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. PBIO’s products are based on the
unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
The company’s primary focus is in the development of high pressure-based
products for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, food science, soil &
plant biology, forensics, and counter-bioterror applications. Additionally,
PBIO is actively expanding the use of its pressure-based technologies in the
following areas: (1) the use of its recently acquired protein disaggregation
and refolding technology from BaroFold, Inc. to allow entry into the biologics
manufacturing and contract research services sector, and (2) the use of its
recently-patented, scalable, high-efficiency, pressure-based Ultra Shear
Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise
immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality,
homogenized, extended shelf-life or room temperature stable low-acid liquid
foods that cannot be effectively preserved using existing non-thermal
technologies.For more information, visit the company’s website at www.PressureBiosciences.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
